These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 15705899

  • 21. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway.
    Calviello G, Di Nicuolo F, Gragnoli S, Piccioni E, Serini S, Maggiano N, Tringali G, Navarra P, Ranelletti FO, Palozza P.
    Carcinogenesis; 2004 Dec; 25(12):2303-10. PubMed ID: 15358633
    [Abstract] [Full Text] [Related]

  • 22. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer.
    Cianchi F, Cortesini C, Schiavone N, Perna F, Magnelli L, Fanti E, Bani D, Messerini L, Fabbroni V, Perigli G, Capaccioli S, Masini E.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6807-15. PubMed ID: 16203768
    [Abstract] [Full Text] [Related]

  • 23. Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts.
    Miura S, Tatsuguchi A, Wada K, Takeyama H, Shinji Y, Hiratsuka T, Futagami S, Miyake K, Gudis K, Mizokami Y, Matsuoka T, Sakamoto C.
    Am J Physiol Gastrointest Liver Physiol; 2004 Aug 01; 287(2):G444-51. PubMed ID: 15246970
    [Abstract] [Full Text] [Related]

  • 24. New cyclooxygenase-2 inhibitor DFU regulates vascular endothelial growth factor expression in rheumatoid synoviocytes.
    Youn J, Cho ML, Kim YJ, Yun HS, Park SH, Jin CZ, Paik DJ, Kim HY.
    Immunol Lett; 2005 Jan 31; 96(2):219-24. PubMed ID: 15585326
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma.
    von Rahden BH, Stein HJ, Pühringer F, Koch I, Langer R, Piontek G, Siewert JR, Höfler H, Sarbia M.
    Cancer Res; 2005 Jun 15; 65(12):5038-44. PubMed ID: 15958546
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Effects of rofecoxib on angiogenesis of pancreatic cancer xenograft in nude mice].
    Zhou XC, Tang CW, Liu CL, Wang CH.
    Ai Zheng; 2004 Apr 15; 23(4):376-80. PubMed ID: 15087022
    [Abstract] [Full Text] [Related]

  • 30. The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture.
    Genç S, Attar E, Gürdöl F, Kendigelen S, Bilir A, Serdaroğlu H.
    Clin Exp Med; 2007 Mar 15; 7(1):6-10. PubMed ID: 17380299
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells.
    Sun WH, Chen GS, Ou XL, Yang Y, Luo C, Zhang Y, Shao Y, Xu HC, Xiao B, Xue YP, Zhou SM, Zhao QS, Ding GX.
    Cancer Lett; 2009 Mar 18; 275(2):247-55. PubMed ID: 19056168
    [Abstract] [Full Text] [Related]

  • 34. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
    Wang J, Shi YQ, Yi J, Ye S, Wang LM, Xu YP, He M, Kong XM.
    J Dig Dis; 2008 Nov 18; 9(4):228-37. PubMed ID: 18959596
    [Abstract] [Full Text] [Related]

  • 35. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.
    Fosslien E.
    Ann Clin Lab Sci; 2001 Oct 18; 31(4):325-48. PubMed ID: 11688844
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of gastric cancer-associated angiogenesis by antisense COX-2 transfectants.
    Fu YG, Sung JJ, Wu KC, Wu HP, Yu J, Chan M, Chan VY, Chan KK, Fan DM, Leung WK.
    Cancer Lett; 2005 Jun 28; 224(2):243-52. PubMed ID: 15914275
    [Abstract] [Full Text] [Related]

  • 37. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor.
    Hasegawa K, Ohashi Y, Ishikawa K, Yasue A, Kato R, Achiwa Y, Nishio E, Udagawa Y.
    Int J Oncol; 2005 May 28; 26(5):1419-28. PubMed ID: 15809736
    [Abstract] [Full Text] [Related]

  • 38. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis.
    Zhao QT, Yue SQ, Cui Z, Wang Q, Cui X, Zhai HH, Zhang LH, Dou KF.
    Life Sci; 2007 Jan 09; 80(5):484-92. PubMed ID: 17097688
    [Abstract] [Full Text] [Related]

  • 39. Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
    Aoki T, Nagakawa Y, Tsuchida A, Kasuya K, Kitamura K, Inoue K, Ozawa T, Koyanagi Y, Itoi T.
    Oncol Rep; 2002 Jan 09; 9(4):761-5. PubMed ID: 12066205
    [Abstract] [Full Text] [Related]

  • 40. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
    Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, Widmer WR, DeGortari AE, Bonney PL, Knapp DW.
    Cancer Res; 2002 Jan 15; 62(2):356-8. PubMed ID: 11809678
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.